Kurv Tesla(TSLA)收益溢價策略主動型ETF TSLP 深 滬
等待開盤 06-25 09:30:00 美东时间
16.88
-0.264
-1.54%
華盛通- 最 高17.26
- 今 開17.26
- 成交量 1.33万股
- 最 低 16.67
- 昨 收 17.1441
- 總市值 1974.96万
- 52周最高 23.819
- 市盈率 靜 --
- 換手率 1.14%
- 52周最低 13.20
- 委 比 0.00%
- 總股本 117.00万
- 歷史最高 23.0395
- 量 比 1.24
- 振 幅 3.44%
- 歷史最低 1.0023
- 每 手 1
- 風險率 2.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多港股异动 | 创新药概念集体冲高，三生制药涨近8%，科伦博泰生物涨近4%，药明康德涨超2%
创新药概念集体冲高，三生制药涨近8%，获董事长增持涉资约786.88万港元；科伦博泰生物涨近4%，药明康德涨超2%>>
06-10 14:14
港股异动 | 超长效抗TSLP抗体II期临床完成首批给药 和铂医药-B(02142.HK)、科伦博泰生物(06990.HK)盘中均涨超5%
和铂医药-B(02142.HK)、科伦博泰生物(06990.HK)今日逆市走高，截至发稿，和铂医药涨3.46%，报9.86港元；科伦博泰生物涨3.82%，报402.2港元。
06-10 14:00
Upstream Bio to Present New Verekitug Data at EAACI 2026, Phase 2 Nasal Polyps Analysis Gets EAACI Oral Presentation
Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that additional data from its Phase 2
06-08 19:21
Aquestive Therapeutics Q1 2026 Earnings Call: Complete Transcript
Aquestive Therapeutics (NASDAQ:AQST) held its first-quarter earnings conference...
05-14 21:09
Keymed Biosciences publishes 2025 annual report
Keymed Biosciences publishes 2025 annual report Keymed Biosciences annual report for year ended Dec. 31, 2025 flagged shift toward dual engine of R&D, commercialization, led by full commercial launch of IL-4Rα antibody Kangyueda. Kangyueda secured NRDL listing in Dec. 2025 for three indications, cov
04-29 17:00
Aclaris Therapeutics to Reveal Clinical Update On Key Biologic And Oral Inhibitor Programs on April 28, 2026
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide the full results
04-28 04:50
Upstream Bio Announces Presentation Of New Data From Phase 2 VIBRANT Trial At American Thoracic Society Meeting On May 18
The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently in clinical development, in chronic
04-17 19:07
Generate Biomedicines publishes corporate presentation on programmable biology drug design platform
Generate Biomedicines publishes corporate presentation on programmable biology drug design platform Generate Biomedicines outlined strategy to use generative biology and scaled lab automation to lower drug-discovery time to proof of concept to 3-5 years from 6-8 years. Company also projected cost to
04-08 19:07
“芯片搬运工”一季度业绩暴涨，净利同比最高预增超87倍！ | 盘后公告精选
存储芯片“批发商”披露一季度业绩预告，千亿锂矿巨头再斥巨资扩产，七连板医药股又提示交易风险......
04-07 21:03
